NeuroPace, Inc. 2023 Form 10-K Summary
Business context and reporting period
NeuroPace is a medical device company focused on its RNS System, a brain-responsive neuromodulation system for adults with drug-resistant focal epilepsy in the United States. The audited filing covers the fiscal year ended December 31, 2023; it is an annual report rather than a standalone fourth-quarter filing.
More than 5,000 patients had received the RNS System by year-end. In 2023, FDA approval of a PMA supplement expanded the qualification criteria for prescribing and implanting centers and clinicians, enabling NeuroPace to target approximately 1,800 additional epileptologists outside Level 4 comprehensive epilepsy centers and functional neurosurgeons. The company also distributes DIXI Medical products and entered a biomarker-monitoring and data-analysis collaboration with Rapport Therapeutics in November 2023.
Financial performance and key metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $65.4 million | $45.5 million | Up 44% |
| Gross profit | $48.1 million | $32.5 million | Up 48% |
| Gross margin | 73.6% | 71.4% | Up 220 basis points |
| Loss from operations | $(27.2) million | $(40.8) million | Improved by $13.6 million |
| Net loss | $(33.0) million | $(47.1) million | Improved by $14.1 million |
| Net loss per share | $(1.27) | $(1.91) | Improved |
| Cash used in operating activities | $(19.7) million | $(36.9) million | Improved by $17.2 million |
- Revenue growth was driven primarily by higher initial-implant unit volume, pricing increases, DIXI Medical sales, and services provided to Rapport. Replacement-procedure revenue declined to approximately 5% of total revenue from 18% in 2022.
- Gross-margin expansion primarily reflected lower fixed manufacturing costs per RNS System unit, partly offset by the lower margin of distributed DIXI Medical products.
- Research and development expense decreased 5% to $20.8 million, while selling, general and administrative expense increased 6% to $54.5 million.
- Interest expense rose to $8.5 million from $7.5 million, reflecting higher term-loan balances from paid-in-kind interest and the increase in the stated interest rate from 12.5% to 13.5%.
- Interest income increased to $3.1 million from $1.6 million because of higher yields on cash and short-term investments.
Balance sheet, liquidity and debt
- Cash, cash equivalents and short-term investments totaled $66.5 million at December 31, 2023, compared with $77.4 million at year-end 2022. Cash and cash equivalents alone were $18.1 million.
- Current liabilities were $16.2 million, and total liabilities were $87.0 million. Stockholders’ equity was $20.7 million.
- Long-term debt was $57.0 million, net of debt discount and issuance costs, compared with $52.9 million in 2022. The term loan bears interest at 13.5%, is secured by substantially all company assets, and includes a 10% repayment fee.
- The term loan is interest-only through September 30, 2025, with principal due in one installment on that date. The company elected paid-in-kind interest for payment dates from April 2022 through December 2023, increasing principal by $4.6 million.
- The term loan requires minimum annual GAAP revenue of $70.0 million for 2024 and minimum cash and cash equivalents of $5.0 million. The company stated that it was in compliance with all covenants at December 31, 2023.
- NeuroPace raised approximately $7.6 million net through its at-the-market offering in November 2023 and had approximately $41.8 million remaining under the program at year-end.
- Management believes existing cash, cash equivalents and short-term investments will fund planned operations for at least 12 months from issuance of the financial statements, but acknowledges that actual cash needs may be higher and additional financing may be required.
Material changes versus the prior comparable period
- Revenue increased 44%, primarily from initial RNS System implants, higher pricing, DIXI Medical distribution revenue and new Rapport services.
- Gross margin improved by 2.2 percentage points, while operating loss and net loss narrowed materially.
- Operating cash burn declined by nearly half, from $36.9 million to $19.7 million, although the company remained cash-flow negative.
- Replacement-procedure revenue declined substantially because the current neurostimulator has an estimated battery life of nearly 11 years.
- Operating assets and liabilities shifted materially: accounts receivable rose to $12.3 million from $7.5 million, inventory rose to $11.2 million from $9.7 million, and deferred revenue increased to $1.1 million from zero.
- Shares outstanding increased to 27.8 million from 25.0 million, reflecting the ATM offering, employee equity activity and other share issuances.
Guidance, outlook, management commentary and risks
- Management expects continued net losses and negative operating cash flows for the next several years while investing in commercial expansion, clinical studies, product enhancements and regulatory activities.
- Growth priorities include expanding adoption beyond Level 4 comprehensive epilepsy centers, increasing clinician and patient awareness, improving referral pathways, leveraging the RNS brain-data platform, and pursuing FDA label expansion for generalized epilepsy and patients ages 12 to 17.
- In December 2023, the company completed enrollment and implantation of the required patients in its generalized-epilepsy clinical trial for an intended FDA submission. Regulatory approval has not yet been obtained.
- The RNS System remains approved only for adults with drug-resistant focal epilepsy in the United States. International sales have not begun.
- Key risks include continued reliance on a single primary product, uncertain market adoption, competition from larger companies, reimbursement changes, clinical and regulatory uncertainty, dependence on single-source suppliers, manufacturing concentration in one Mountain View facility, product liability, cybersecurity and privacy exposure, intellectual-property challenges, and the need for additional capital.
- The company has a history of recurring losses and an accumulated deficit of $503.8 million at year-end. Failure to meet the 2024 revenue covenant could permit lenders to accelerate the term loan and create a need for additional capital.
- The company reported no material pending legal proceedings or accrued contingent liabilities at year-end. Management concluded that disclosure controls and internal control over financial reporting were effective; the external auditor was not required to provide an internal-control attestation because NeuroPace remains an emerging growth company.
Most important facts for investors to verify
- Whether revenue growth and initial-implant volume continue at a pace sufficient to meet the $70.0 million 2024 minimum revenue covenant.
- Cash burn, remaining liquidity and the company’s ability to refinance or repay the term loan’s September 2025 maturity, including the repayment fee.
- Whether expansion beyond Level 4 centers produces sustainable revenue and acceptable gross margins.
- Progress, results and FDA decisions related to generalized-epilepsy and adolescent indications.
- The revenue and margin contribution of DIXI Medical distribution and Rapport collaboration services.
- Future dilution from the remaining ATM capacity, equity awards and other potential financings.
- Supply continuity for single-source batteries, printed circuit assemblies and other critical components.
- Any adverse clinical, regulatory, reimbursement, product-liability, cybersecurity or intellectual-property developments.